Peter Ordentlich Selected Research

Granzymes (Granzyme)

1/2020

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Ordentlich Research Topics

Disease

12	Neoplasms (Cancer) 01/2020 - 09/2008
5	Breast Neoplasms (Breast Cancer) 08/2017 - 11/2009
4	Carcinoma (Carcinomatosis) 01/2020 - 01/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Disease Progression 01/2021
1	Inflammation (Inflammations) 01/2020
1	Embryonal Rhabdomyosarcoma 01/2019
1	Alveolar Rhabdomyosarcoma 01/2019
1	Residual Neoplasm 01/2019
1	Triple Negative Breast Neoplasms 08/2017
1	Inflammatory Breast Neoplasms 08/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017
1	Pericardial Effusion 01/2016
1	Pericarditis 01/2016
1	Hodgkin Disease (Hodgkin's Disease) 01/2016
1	Obesity 06/2004
1	Leukemia 07/2003
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2003
1	Crohn Disease (Crohn's Disease) 07/2003

Drug/Important Bio-Agent (IBA)

11	entinostat (MS 275)IBA 01/2020 - 11/2009
8	Histone Deacetylase InhibitorsIBA 01/2020 - 11/2009
3	Pharmaceutical PreparationsIBA 08/2017 - 07/2003
3	Protein Isoforms (Isoforms)IBA 01/2016 - 11/2009
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2017
2	Interleukin-15 (Interleukin 15)IBA 01/2020 - 01/2019
2	AntigensIBA 01/2020 - 01/2019
2	CytokinesIBA 01/2020 - 01/2017
2	VaccinesIBA 01/2020 - 01/2019
2	ChemokinesIBA 11/2017 - 01/2017
2	Histone Deacetylases (Histone Deacetylase)IBA 07/2014 - 11/2009
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Granzymes (Granzyme)IBA 01/2020
1	Cancer VaccinesIBA 01/2020
1	ALT-803IBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2019
1	Hematoxylin (Haematoxylon)IBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Interleukin-12 (IL 12)IBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2017
1	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 08/2017
1	Sirolimus (Rapamycin)FDA Link 01/2017
1	Drug CombinationsIBA 01/2017
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2016
1	Estrogen ReceptorsIBA 01/2016
1	RetinoidsIBA 01/2016
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2016
1	Antineoplastic Agents (Antineoplastics)IBA 01/2016
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2016
1	exemestane (Aromasin)FDA Link 01/2016
1	AntibodiesIBA 01/2016
1	Immunoconjugates (Immunoconjugate)IBA 01/2016
1	Aromatase InhibitorsIBA 01/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Apoptosis Regulatory ProteinsIBA 07/2014
1	Indicators and Reagents (Reagents)IBA 07/2014
1	Tyrosine Kinase InhibitorsIBA 07/2014
1	Lapatinib (GW572016)FDA Link 07/2014
1	Trastuzumab (Herceptin)FDA Link 07/2014
1	Growth Factor ReceptorsIBA 11/2009
1	CarcinogensIBA 09/2008
1	ERRalpha Estrogen-Related ReceptorIBA 06/2004
1	purineIBA 07/2003
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 07/2003

Therapy/Procedure

7	Therapeutics 01/2021 - 11/2009
2	Immunotherapy 01/2020 - 01/2019
1	Drug Therapy (Chemotherapy) 01/2019